GlassScriptPhysician profile
Parastoo Jangouk
NPI 1528324787
$45,766.49
in general payments reported to CMS, 2019-2025
37 companies · $3,643 in 2025
The $3,643 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.23 · 2020: $458 · 2021: $5,489 · 2022: $10K · 2023: $13K · 2024: $13K · 2025: $3,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $9,584 · Travel and Lodging: $3,279 · Education: $51.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,575.00 |
| Food and Beverage | $9,584.49 |
| Travel and Lodging | $3,279.47 |
| Education | $51.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29,325.98 | 2021-2025 | Omvoh |
| Eli Lilly and Company | $4,512.13 | 2021-2025 | |
| Abbvie INC. | $3,546.91 | 2019-2025 | |
| Mahana Therapeutics, INC. | $1,275.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,161.29 | 2020-2025 | Xifaxan, Trulance |
| Pfizer INC. | $837.84 | 2022-2025 | |
| Celgene Corporation | $682.90 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $527.01 | 2021-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $398.98 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $302.93 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $284.94 | 2022-2025 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $270.32 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Gilead Sciences, INC. | $257.15 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $247.12 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $215.72 | 2024-2025 | Zenpep, Vowst |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $213.53 | 2020 | |
| Medtronic, INC. | $210.37 | 2025 | Interstim, Dragonfly Pancreaticobiliary Scope and Instrument Channel Caps |
| Ardelyx, INC. | $204.74 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $194.31 | 2019-2025 | Gattex, Entyvio |
| Celltrion USA INC. | $172.52 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $124.31 | 2022-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $102.91 | 2021-2023 | |
| Axonics, INC. | $101.75 | 2020 | |
| Pharmacosmos Therapeutics INC. | $94.67 | 2020-2021 | |
| Boston Scientific Corporation | $76.17 | 2022-2023 | |
| Madrigal Pharmaceuticals | $62.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $60.94 | 2022-2023 | Injectafer |
| Organon LLC | $60.14 | 2023 | Renflexis, Hadlima |
| Ipsen Biopharmaceuticals, INC | $56.37 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $44.73 | 2023-2025 | Sutab, Suflave |
| Blueprint Medicines Corporation | $41.84 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $36.06 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $17.86 | 2021 | |
| Amgen INC. | $15.54 | 2025 | Uplizna |
| Novo Nordisk INC | $14.67 | 2025 | Wegovy |
| Orphalan INC | $14.32 | 2025 | Cuvrior |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,285.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parastoo Jangouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.